Replies to post #24183 on Can B Corp (CANB)

[DarthYoda]

"The U.S. Food and Drug Administration (FDA) does not have the authority to review dietary supplement products for safety and effectiveness before they are marketed."

https://www.fda.gov/food/buy-store-serve-safe-food/what-you-need-know-about-dietary-supplements

[sleekscape]

Thank you for providing factual information in defense of your argument, instead of proclaiming that the most unsettled issue in the cannabinoid industry today (the ultimate fate of the secondary cannabinoids) has been “put to bed” without providing any meaningful information or analysis that would buttress that argument

As I’ve already stated on multiple occasions recently, there are 3 different significant factors that will determine whether other cannabinoids outside of CBD will be permitted by the FDA in dietary supplements and food products

1) IND preclusion — the FDA hasn’t publicly commented on this as of yet, but this is not a settled issue for many of the other cannabinoids which have been studied for a number of years

2) Safety Data — there is far more safety data on CBD than on CBG, CBC, CBN, etc

So if the FDA still isn’t satisfied with the safety data on CBD, where does that leave the other cannabinoids?

3) Preserving incentives for pharma to perform research on CBG, CBC, CBN, etc


If there is any authentic interest on the board in doing so, we can further explore the IND preclusion issue with secondary cannabinoids

However, as CANB is a Pure CBD Oil stock, I also don’t want to needlessly clutter the board talking about CBG, CBN, CBC, etc

So let me know either way

If there is some authentic interest, I’ll lay some cards out on the table with respect to secondary cannabinoids, and then we can move on from there and continue to focus on the most pressing issue for CANB shareholders right now — what will the FDA and Congress decide to do with CBD in Dietary Supplements and Foods?


Sleek